# Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

> **NCT04230499** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Rapamycin Holdings Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Familial Adenomatous Polyposis

## Interventions

- **DRUG:** Encapsulated Rapamycin (eRapa)

## Key facts

- **NCT ID:** NCT04230499
- **Lead sponsor:** Rapamycin Holdings Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-01-18
- **Primary completion:** 2025-03
- **Final completion:** 2025-03
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-01-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04230499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04230499, "Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04230499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*